Myriad Discloses Network Breach; Testing Operations Temporarily Suspended
MYGN has more than doubled off its 52-week low of $2.74.
Summary
Myriad Genetics disclosed unauthorized access to its IT network on November 2, 2026, temporarily suspending testing operations and order management systems. Most systems are back online and the company says it does not expect a material impact, but the investigation into whether patient records were accessed is ongoing.
Key Events · Legal and Risk Events · MYGN
-
Network Breach Detected November 2
On November 2, 2026, Myriad detected unauthorized access within its information technology network environment and initiated incident response procedures to contain the activity.
-
Testing Operations Temporarily Suspended
Testing operations and order management systems were temporarily suspended, and certain system credentials were reset; most systems have since returned to normal operations.
-
Patient Records Question Unresolved
The full scope of unauthorized access remains under investigation, including whether any patient records were accessed on systems that contain patient information. External experts have been engaged.
-
Company Sees No Material Impact
As of the filing date, Myriad does not believe the incident will have a material adverse effect on its business, though it flags legal, regulatory, reputational and financial risks from the incident or additional incidents.
Analysis · MYGN · Life Sciences
The breach strikes at the lab operations that generate Myriad's revenue: unauthorized access was detected in its IT network on November 2, prompting a shutdown of testing and order management systems while the company investigates. Management says most systems are back and does not expect a material adverse effect, but the scope remains unresolved, including whether patient records were accessed. That open question carries legal, regulatory and reputational exposure on top of the operational disruption, and it lands days after a $43.9 million quarterly loss and a pending $210 million prenatal-business sale to Labcorp.
How filings like this one have moved
In the 30 days to Nov 5, 2026, 33.4% of the 2397 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MYGN was trading at $6.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $575.8M. The 52-week trading range was $2.74 to $8.09. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.